Godavari Biorefineries Ltd has secured a United States patent for a novel compound designed to treat cancer. The invention, titled "5-Hydroxy-1,4-Naphthalenedione for Use in the Treatment of Cancer," demonstrates significant potential against breast and prostate cancers.

The patent protects a class of compounds that effectively inhibit both general cancer cells and cancer stem cells. This intellectual property right grants the company exclusive rights to exclude others from making, using, or selling the invention within the United States.

Patent Details and Scope

The grant was issued by the United States Patent and Trademark Office (USPTO). The disclosure was made to stock exchanges on October 14, 2026, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The patent ensures that Godavari Biorefineries holds the legal authority to prevent competitors from importing or selling products derived from this specific process in the US market, subject to maintenance fees as per US law.

Godavari Biorefineries Ltd received a patent grant from the Mexican Patent Office on October 2, 2026. The patent covers the use of specific compounds for treating viral infections by inhibiting V-ATPase activity in cells.

The invention details the use of these compounds in the manufacture of medicaments for viral infection treatment. This disclosure was made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Patent details and validity

The Mexican Patent Office granted the patent titled "Use of compounds for treating viral infections" to Godavari Biorefineries Limited. The grant certificate confirms the ownership and scope of the intellectual property rights.

The patent is valid for twenty years, counted from the date of the international application filing. It expires on May 10, 2041, subject to the payment of maintenance fees as required by law.

Technical scope and inventors

The patent classifies the compounds under several International Patent Classification (IPC) and Cooperative Patent Classification (CPC) codes, including A61K31/4709 and A61K31/36. These classifications relate to medicinal preparations containing organic active ingredients.

The inventors listed in the patent are Maithili Athavale, Sandip Gavade, Prashant Kharkar, and Sangeeta Srivastava. The company holds the domicile at Somaiya Bhavan, Mumbai.

Regulatory compliance

Godavari Biorefineries informed both the National Stock Exchange of India Limited and BSE Limited about this development. The company secretary and compliance officer, Manoj Jain, signed the disclosure letter digitally on October 2, 2026.

This grant adds to the company's portfolio of intellectual property assets in the biotechnology and pharmaceutical sectors. The patent was issued by the Instituto Mexicano de la Propiedad Industrial (IMPI).